UpdatesFDA VoicesFDA Promotes Clinical Trial Innovation
By: Hilary Marston, MD, MPH, Chief Medical Officer and Kevin Bugin, PhD, Deputy Director of Operations in the Office of New Drugs, Center for Drug Evaluation and Research
Breakthroughs in science and technology are advancing innovation in more areas of medicine, providing novel treatment options for patients. The scientific community has a deepening understanding of disease and human biology, and of the enormous potential afforded through new technologies.
The same spirit of innovation is enhancing the design and conduct of clinical research. As the FDA observes Clinical Trials Day, we reflect on the progress made and the widespread efforts underway to advance clinical trial innovation. This progress has been possible because of clinical trial participants and their families, health care professionals, medical product developers, federal partners and the entire clinical research community. |
Guidance DocumentsCVM GFI #115 (VICH GL22) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Toxicity Testing (Revision 1)
The objective of this guidance is to ensure international harmonization of reproduction toxicity testing, which is appropriate for the evaluation of effects on reproduction from long-term, low-dose exposures, such as may be encountered from the presence of veterinary drug residues in food. View all Official FDA Guidance Documents and other Regulatory Guidance
You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period. Webinars and Virtual WorkshopsOTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2024 User Fees and Registration
June 18, 2024; 1:00 - 2:00 p.m. ET
The webinar provides an overview of the Over-the-Counter Drug User Fee Program (OMUFA) and describes the key elements of the program as it relates to OMUFA user fees. FDA WORKSHOP: 9th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop
June 25, 2024; 11:00 a.m. - 2:30 p.m. ET
The FDA Oncology Center of Excellence (OCE) Patient-Focused Drug Development (PFDD) program welcomes you to the Clinical Outcome Assessment in Cancer Clinical Trials (COA-CCT) 9th annual workshop. View Upcoming FDA Meetings, Conferences and Workshops
Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts About UsThe Stakeholder Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, consumer groups, trade associations, patient advocacy organizations, think tanks/academia, and other stakeholders, in order to better inform our policy making process, identify policy hurdles or stakeholder misconceptions, and create strategic collaborations. For more information, please contact us at: FDAStakeholderEngagement@fda.hhs.gov. |